De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine
| Autor: | Emilie Panicucci, Mikael Cohen, Christine Lebrun, Pierre Thomas, Véronique Bourg, F. Rocher |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male Multiple Sclerosis 03 medical and health sciences chemistry.chemical_compound Multiple Sclerosis Relapsing-Remitting Status Epilepticus 0302 clinical medicine Potassium Channel Blockers medicine Humans In patient 030212 general & internal medicine 4-Aminopyridine Convulsive status epilepticus business.industry Multiple sclerosis Potassium channel blocker Middle Aged medicine.disease Baclofen Neurology chemistry Anesthesia Female Neurology (clinical) Extended release Nerve conduction business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Multiple Sclerosis Journal. 25:618-621 |
| ISSN: | 1477-0970 1352-4585 |
| DOI: | 10.1177/1352458518790379 |
| Popis: | Background: Dalfampridine extended release (DAL) is a broad-spectrum voltage-gated potassium channel blocker that is indicated in multiple sclerosis to improve the nerve conduction of demyelinated axons. Seizures are a known side effect of DAL, which is contraindicated in patients with a history of epilepsy. Objective: Three cases of multiple sclerosis (MS) with de novo convulsive status epilepticus (CSE) probably related to dalfampridine administration are described. Methods: No patients had a history of seizures or renal impairment. Biological tests were normal. A brain magnetic resonance imaging (MRI) showed diffuse cortical and subcortical atrophy without active inflammatory lesions. Results: All three patients presented with CSE that was attributed to DAL and so was discontinued. Conclusion: These case reports illustrate that, aside from seizures, de novo CSE is a potential complication of MS patients treated with DAL. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|